JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
| Condition(s) | Non-Small Cell Lung Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Summary | To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC |
| Who can participate | 1.0 Inclusion Criteria 1.1 Age \> 18 years. 1.2 ECOG/Zubrod performance status (PS) 0, 1, or 2 (reference Appendix C). 1.3 Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater. 1.4 The primary tumor in the lung must be biopsy confirmed non-small cell lung cancer within 180 days prior to randomization. 1.5 Tumor ≤ 4 cm maximum diameter, including clinical stage IA and selected IB by PET or PET integrated with a simultaneous CT scan (PET-CT) of the chest and upper abdomen performed within 180 days prior to randomization (reference Appendix A \& B). Repeat imaging within 90 days prior to randomization is recommended for re-staging but is not required based on institutional norms. 1.6 All clinic |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University of Texas Southwestern Medical Center |
| Locations | La Jolla, California, United States; Aurora, Colorado, United States; Colorado Springs, Colorado, United States; Boca Raton, Florida, United States; Savannah, Georgia, United States; Iowa City, Iowa, United States (+44 more sites) |
| Start date | 2015-07 |
| NCT ID | NCT02468024 |
| Official listing | https://clinicaltrials.gov/study/NCT02468024 |